MetaCap

Akebia Therapeutics (AKBA) vs Immunic (IMUX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Immunic (IMUX) has outperformed Akebia Therapeutics (AKBA) over the past year, gaining 1.9% versus a loss of 75.1%. Over five years, AKBA leads with a -85.6% price change compared with -91.9% for IMUX. Immunic is the larger company by market cap ($111.0 million vs $107.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AKBA-75.13%IMUX+1.90%
+157%+36%-86%
Nov 21, 20251 yearNov 20, 2026
AKBA-86.13%IMUX-92.54%
+52%-25%-101%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AKBA versus IMUX key metrics
MetricAKBAIMUX
Share price$0.3855$6.99
Market cap$107.04M$111.01M
1-day change-8.71%-5.41%
YTD return-76.06%+30.90%
1-year return-75.13%+1.90%
5-year return-85.56%-91.88%
EPS (TTM)$-0.17$-3.53
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$236.20M—
Revenue growth (YoY)+47.46%—
Net income (latest FY)$-5.34M$-97.17M
Gross margin83.29%—
Operating margin9.95%—
Net margin-2.26%—
52-week high$1.73$17.43
52-week low$0.361$5.06
Distance from 52-week high-77.72%-59.90%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+678.21%+508.73%
Average volume8.05M343.44K
Shares outstanding277.66M15.88M
Employees194100
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • IMUX has outperformed AKBA by 77.0 percentage points over the past year.

About Akebia Therapeutics

AKBA stock →

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD.

Health Care · Biotechnology: Pharmaceutical Preparations · 194 employees

About Immunic

IMUX stock →

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.

Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees

AKBA vs IMUX FAQ

Which is bigger, Akebia Therapeutics or Immunic?

Immunic (IMUX) is larger, with a market capitalization of $111.01M compared with $107.04M for Akebia Therapeutics (AKBA).

Which stock has performed better over the past year, AKBA or IMUX?

IMUX returned +1.90% over the past 12 months, compared with -75.13% for AKBA (price return, excluding dividends). Past performance does not predict future results.

Are Akebia Therapeutics and Immunic in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons